Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response
Soukup et al.
Papers
Scientific Reports
September 2017
Authors and Affiliates
Klara Soukup1,4, Angela Halfmann1, Barbara Dillinger1, Fiona Poyer1, Katharina Martin1, Bernadette Blauensteiner1, Maximilian Kauer2, Mario Kuttke3, Gernot Schabbauer3 & Alexander M. Dohnal1,5
1Tumour Immunology, St. Anna Kinderkrebsforschung, Children’s Cancer Research Institute, Vienna, Austria. 2Bioinformatics, St. Anna Kinderkrebsforschung, Children’s Cancer Research Institute, Vienna, Austria. 3Institute for Physiology, Centre for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. 4Present address: Department of Fundamental Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. 5Present address: APEIRON Biologics AG, Vienna, Austria